Publications

Final results from the Phase I study expansion cohort of the selective FGFR inhibitor Debio 1347 in patients with solid…

Debio 1143 Mode of Action: a Broad Chemo-Radio and Immuno-Therapy Sensitizer

Squamous Cell Carcinoma Of The Head & Neck (SCCHN) – Infographic

Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma – Results of the Lumed Phase 0a Study

DEBIO 1347 In Patients With GastroIntestinal Cancers Harboring An FGFR Gene Fusion: Preliminary Results

A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid…

FUZE Clinical Trial: a Phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of the tumor histology

New sample preparation method enabling PCR-based pathogen identification directly from blood to accelerate blood stream infection (BSI) diagnosis

Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients…